Abstract: Nucleic acid expression control sequence cassettes and vectors containing the same are provided for use in making abundant quantities of recombinant polypeptides of interest. The modified transcriptional control sequences, which include a T5 promoter sequence, are highly stable and can be used in a variety of vectors, such as plasmids.

Abstract: Streptococcus proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.

Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.

Abstract: The present disclosure relates to compositions and methods for treating or preventing coronavirus infections. For example, compositions are provided that comprise a coronavirus S protein or N protein, fragment, or variant thereof, capable of eliciting a protective humoral and/or cell-mediated immune response, which compositions are useful for treating or preventing infection by coronavirus, such as the causative agent of SARS. Also, coronavirus S protein and N protein immunogen compositions are provided that include an adjuvant, such as Proteosome or Protollin, which may be used for treating or preventing infection caused by a coronavirus, such as a SARS coronavirus.

Abstract: Streptococcus proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.

Abstract: A method for detecting the presence of a vancomycin-resistant microorganism in a biological sample using a single chimeric probe in a cycling probe reaction.

Abstract: Compositions useful for treating neurological disorders including neurodegenerative disorders associated with deleterious protein aggregation, aberrant protein folding, such as brain amylogenic diseases, and/or neurodegenerative autoimmune disorders are described. Methods of using said compositions also are described. In particular, methods to treat a neurodegenerative disorder such as Alzheimer's disease and a neurodegenerative autoimmune disorder such as Multiple Sclerosis are contemplated utilizing proteosomes and/or Glatiramer Acetate, wherein the GA is in a submicron emulsion or a nanoemulsion.

Abstract: Streptococcus polypeptides and polynucleotides encoding them are disclosed. The polypeptides may be useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.

Abstract: Nucleic acid expression control sequence cassettes and vectors containing the same are provided for use in making abundant quantities of recombinant polypeptides of interest. The modified transcriptional control sequences, which include a T5 promoter sequence, are highly stable and can be used in a variety of vectors, such as plasmids.

Abstract: Nucleic acid expression control sequence cassettes and vectors containing the same are provided for use in making abundant quantities of recombinant polypeptides of interest. The modified transcriptional control sequences, which include a T5 promoter sequence, are highly stable and can be used in a variety of vectors, such as plasmids.

Abstract: Compositions and methods for making and using therapeutic formulations of measles virus antigens with a Proteosome-based adjuvant are provided. The measles virus antigens may be derived from a variety of sources, such as from recombinant production or from a split antigen preparation. The measles vaccine formulations may be used, for example, in methods for treating or preventing a measles virus infection and eliciting a protective immune response.

Abstract: The present invention relates generally to methods of treating or preventing RSV infections, and more specifically, to compositions, and the use thereof, comprising one or more RSV G protein immunogen or fragment thereof capable of eliciting protective immunity without eliciting an immunopathological response or eliciting a reduced immunopathological response.

Abstract: Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.

Abstract: Improved forms of vaccines which comprise proteosomes and protein antigens are described. Vaccines which contain influenza HA as the antigen are used for illustration as to demonstrate efficacy. Improvements in the preparation of the vaccines themselves and the proteosome component are also included.

Abstract: Improved forms of vaccines which comprise proteosomes and protein antigens are described. Vaccines which contain influenza HA as the antigen are used for illustration as to demonstrate efficacy. Improvements in the preparation of the vaccines themselves and the proteosome component are also included.

Abstract: A method for detecting the presence of a vancomycin-resistant microorganism in a biological sample using a single chimeric probe in a cycling probe reaction.

Abstract: Nucleic acid expression control sequence cassettes and vectors containing the same are provided for use in making abundant quantities of recombinant polypeptides of interest. The modified transcriptional control sequences, which include a T5 promoter sequence, are highly stable and can be used in a variety of vectors, such as plasmids.

Abstract: Compositions and methods are provided for determining the presence of an antibiotic resistant mecA gene in a biological sample, comprising the general steps of (a) treating cells contained within a biological sample to expose target single-stranded nucleic acid molecules; (b) reacting the target single-stranded nucleic acids with a scissile link-containing nucleic acid which is complementary to a portion of an antibiotic resistant mecA gene, and with an enzyme which cleaves double-stranded target-probe complexes, under conditions which allow the target and probe to hybridize to each other to form a double-stranded target-probe complex, the enzyme molecule being capable of cleaving the scissile link of the target-probe complex such that one or more fragments of the nucleic acid probe released from said complex; and (c) determining whether cleaved portions of the detecting probe fragments released from said nucleic acid probe are produced, and thereby detecting the presence of the antibiotic resistant mecA gene

Abstract: A continuous method for preparing proteosome-amphiphilic determinant vaccines for parenteral or mucosal administration using diafiltration or ultrafiltration technology. The amphiphilic determinants include lipopolysaccharides from gram negative bacteria, e.g. S. flexneri, P. shigelloides and S. sonnei. Proteosomes are obtained from group B type 2b meningococci. The active proteosome-amphiphilic determinant complexes (non-covalent complexes) of the vaccine are formed using diafiltration or ultrafiltration to remove the detergent under non-static conditions. The use of diafiltration or ultrafiltration decreases processing time and the opportunity for contamination and further permits the use of ambient temperature and efficient scale-up. In addition, the process permits the reliable and continuous monitoring of the dializate which enhances the efficiency of the entire process.

Abstract: A method for determining the presence of vancomycin antibiotic resistant gene of enterococci in a biological sample, comprising the steps of (a) treating cells contained within the biological sample to expose single stranded-target nucleic acid molecules; (b) reacting the target single-stranded cellular nucleic acids with probe(s) nucleic acid sequence complementary to a portion of the antibiotic vancomycin resistant gene and the probe having a scissile linkage, and with an enzyme molecule, under conditions, which allow the target and probe to hybridize to each other and form a double-stranded, target-probe complex, the enzyme molecule being capable of cleaving the scissile link of the target-probe complex such that one or more fragments of the nucleic acid probe is released from said complex; and (c) determining whether cleaved portions of the nucleic acid probe are produced, and thereby detecting the presence of a vancomycin antibiotic resistant gene.